Company intelligence / Profile preview
Serna Bio
Brampton / Toronto area, Ontario, Canadaserna.bio ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
Serna Bio has developed a proprietary AI-driven platform to discover small molecules that target functional RNA motifs to modulate translation/splicing. The company remains preclinical with no public clinical results yet but claims significant advances in mapping the druggable transcriptome. No published clinical data as of May 2025.
- Therapeutic areas
- OtherOncology
- Modalities
- Small molecules targeting RNA
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on Serna Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Serna Bio.